ANGO Angiodynamics (ANGO) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001275187
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
86
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $0 priced
What the filings say about ANGO
Insiders, 180 days
-$344.0K net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-07-16
Planned sales (Form 144), 90 days
$344.0K
1 notice
Angiodynamics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ANGIODYNAMICS INC insiders sold a net $344.0K of stock across 22 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on Jan 16, 2025.
- +81.4% median (+81.4% mean) 90-day return after 2 previous buys.
- The trade is 36.1% of the 64,745 shares held after it.
- No other insider sold within 30 days.
- 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP Quality and Regulatory Nighan Warren JR sold about $344.0K of ANGO on Jul 30, 2026, the largest insider sale at the company on our record; 86 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 10.7% of the 93,597 shares held after it.
- 2 other insiders bought within 30 days.
- 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Legal Officer Weiss Lawrence T bought about $118.1K of ANGO on Oct 21, 2025, the largest insider purchase at the company since 2024; 2 other insiders bought within 30 days and 86 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Oct 8, 2024.
- +4.6% median (+19.4% mean) 90-day return after 3 previous buys.
- The trade is 0.3% of the 256,629 shares held after it.
- 2 other insiders bought within 30 days.
- 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP and CFO Trowbridge Stephen A bought about $9.9K of ANGO on Oct 13, 2025; 2 other insiders bought within 30 days and 86 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Oct 7, 2024.
- -1.3% median (+8.2% mean) 90-day return after 4 previous buys.
- The trade is 1.1% of the 882,529 shares held after it.
- 2 other insiders bought within 30 days.
- 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Clemmer James C bought about $111.5K of ANGO on Oct 9, 2025, the largest insider purchase at the company since 2024; 2 other insiders bought within 30 days and 86 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Oct 10, 2024.
- +81.4% median (+81.4% mean) 90-day return after 2 previous buys.
- The trade is 9.7% of the 41,817 shares held after it.
- No other insider sold within 30 days.
- 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP Quality and Regulatory Nighan Warren JR sold about $50.0K of ANGO on Jan 16, 2025, the largest insider sale at the company since 2023; 86 funds added in the latest 13F quarter.22 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$344.0K over 180 days
-$344.0K over 90 days
below 55% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
86 funds bought in last quarter
more than 59% of Medical Devices
Revenue
+9.5% year over year
more than 50% of Medical Devices
Margin
-11.5% net margin
more than 54% of Medical Devices
Buybacks
no share repurchases reported
Short interest
4.0% of the float short (float per yahoo 2026-10-26) · 2.2 days to cover · settled 2026-09-30
below 54% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ANGO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+2.2%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ANGO: institutional holders (13F)
13F holdings, latest reported quarter
3,803,232 sh
$49.5M
3,062,517 sh
$39.8M
2,640,214 sh
$34.3M
2,198,000 sh
$28.6M
1,969,835 sh
$25.6M
Congress trades in ANGO
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-07-16 · disclosed 9 days later
$1,001 - $15,000
Bought 2025-06-27 · disclosed 28 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ANGO planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
WARREN NIGHAN
Filed 2026-07-30
$344.0K
ANGO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Dunham Small Cap Growth Fund
$1.2M position · as of 2026-07-31
1.5%
Paradigm Micro-Cap Fund
$2.6M position · as of 2026-06-30
1.4%
Royce Small-Cap Opportunity Fund
$9.2M position · as of 2026-06-30
0.7%
SBH SMALL CAP VALUE FUND
$2.7M position · as of 2026-06-30
0.6%
Transamerica Small Cap Value
$636.0K position · as of 2026-07-31
0.6%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$795.9K position · as of 2026-06-30
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
14 registered trials, 10 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 3
1 active
1
Phase 4
1 active
12
Not applicable
8 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Mr. Clemmer
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$5.5M
$6.8M
$1.5M
-56%
-57%
2023
$5.0M
$971.1K
$1.3M
-38%
-47%
2022
$4.0M
-$2.1M
$914.2K
-7%
-30%
2021
$5.7M
$5.0M
$1.3M
+92%
-27%
2020
$4.0M
$13.9M
$1.0M
+126%
+24%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $344.0K sold by insiders over 180 days, 86 funds added last quarter, $344.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ANGO financials
Revenue growth
+9.5%
XBRL, annual
Net margin
-11.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$325.4M
four quarters, 2025-09-01 to 2026-08-31
Revenue, TTM ANGO
| FY May 2026 | $320.2M |
| FY May 2025 | $292.5M |
| FY May 2024 | $303.9M |
| FY May 2023 | $338.8M |
| FY May 2022 | $316.2M |
| Aug 2026 | $80.9M |
| May 2026 | $86.6M |
| Feb 2026 | $78.4M |
| Nov 2025 | $79.4M |
| Aug 2025 | $75.7M |
| May 2025 | $80.2M |
| Feb 2025 | $72.0M |
| Nov 2024 | $72.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-10.1%
net income over revenue, 2025-09-01 to 2026-08-31
Net margin, TTM ANGO
| FY May 2026 | -11.5% |
| FY May 2025 | -11.6% |
| FY May 2024 | -60.7% |
| FY May 2023 | -15.5% |
| FY May 2022 | n/a |
| Aug 2026 | -8.8% |
| May 2026 | -13.2% |
| Feb 2026 | -10.3% |
| Nov 2025 | -8.0% |
| Aug 2025 | -14.4% |
| May 2025 | -7.5% |
| Feb 2025 | -6.1% |
| Nov 2024 | -14.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.4M
operating cash flow minus capex, 2025-09-01 to 2026-08-31
Free cash flow, TTM ANGO
| FY May 2026 | $508.0K |
| FY May 2025 | -$14.6M |
| FY May 2024 | -$30.7M |
| FY May 2023 | -$3.7M |
| FY May 2022 | -$11.5M |
| Aug 2026 | -$15.7M |
| May 2026 | $17.0M |
| Feb 2026 | -$4.1M |
| Nov 2025 | $4.2M |
| Aug 2025 | -$16.6M |
| May 2025 | $18.0M |
| Feb 2025 | -$15.0M |
| Nov 2024 | $1.7M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
LongTermDebt as filed 2024-05-31 (27 months older than the period end) (includes the current portion); equity 2026-08-31
Debt to equity ANGO
| FY May 2026 | 0.00x |
| FY May 2025 | 0.00x |
| FY May 2024 | 0.00x |
| FY May 2023 | 0.13x |
| FY May 2022 | 0.06x |
| Aug 2026 | 0.00x |
| May 2026 | 0.00x |
| Feb 2026 | 0.00x |
| Nov 2025 | 0.00x |
| Aug 2025 | 0.00x |
| May 2025 | 0.00x |
| Feb 2025 | 0.00x |
| Nov 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt ANGO
| FY May 2026 | n/a |
| FY May 2025 | n/a |
| FY May 2024 | n/a |
| FY May 2023 | 0.00x |
| FY May 2022 | -0.29x |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-19.2%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on equity ANGO
| FY May 2026 | -20.8% |
| FY May 2025 | -17.5% |
| FY May 2024 | -63.1% |
| FY May 2023 | -13.1% |
| FY May 2022 | n/a |
| Aug 2026 | -19.2% |
| May 2026 | -20.8% |
| Feb 2026 | -17.5% |
| Nov 2025 | -15.3% |
| Aug 2025 | -17.1% |
| May 2025 | -17.5% |
| Feb 2025 | -20.5% |
| Nov 2024 | -76.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-13.0%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on assets ANGO
| FY May 2026 | -13.4% |
| FY May 2025 | -11.4% |
| FY May 2024 | -43.4% |
| FY May 2023 | -9.7% |
| FY May 2022 | n/a |
| Aug 2026 | -13.0% |
| May 2026 | -13.4% |
| Feb 2026 | -11.5% |
| Nov 2025 | -9.9% |
| Aug 2025 | -11.5% |
| May 2025 | -11.4% |
| Feb 2025 | -13.6% |
| Nov 2024 | -56.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ANGO
| FY May 2026 | n/a |
| FY May 2025 | n/a |
| FY May 2024 | n/a |
| FY May 2023 | n/a |
| FY May 2022 | n/a |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-19.3%
operating income (EBIT proxy) over average of 2025-08-31 and 2026-08-31 minus current liabilities
Return on capital employed ANGO
| FY May 2026 | -20.1% |
| FY May 2025 | -18.6% |
| FY May 2024 | -57.0% |
| FY May 2023 | -11.0% |
| FY May 2022 | -5.8% |
| Aug 2026 | -19.3% |
| May 2026 | -20.1% |
| Feb 2026 | -17.7% |
| Nov 2025 | -16.2% |
| Aug 2025 | -18.1% |
| May 2025 | -18.6% |
| Feb 2025 | -21.8% |
| Nov 2024 | -76.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ANGO
| FY May 2026 | n/a |
| FY May 2025 | n/a |
| FY May 2024 | n/a |
| FY May 2023 | n/a |
| FY May 2022 | n/a |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$481.6M
market value at close 2026-10-27 on 2026-10-07 shares, plus LongTermDebt as filed 2024-05-31 (27 months older than the period end) (includes the current portion), minus cash 2026-08-31
Enterprise value ANGO
| FY May 2026 | $420.5M |
| FY May 2025 | $358.3M |
| FY May 2024 | $176.7M |
| FY May 2023 | $376.4M |
| FY May 2022 | $757.4M |
| Aug 2026 | $632.7M |
| May 2026 | $420.5M |
| Feb 2026 | $433.7M |
| Nov 2025 | $469.2M |
| Aug 2025 | $378.1M |
| May 2025 | $358.3M |
| Feb 2025 | $331.2M |
| Nov 2024 | $227.5M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+0.3%
TTM free cash flow over market value at close 2026-10-27
FCF yield ANGO
| FY May 2026 | +0.1% |
| FY May 2025 | -3.5% |
| FY May 2024 | -12.1% |
| FY May 2023 | -1.0% |
| FY May 2022 | -1.5% |
| Aug 2026 | +0.2% |
| May 2026 | +0.1% |
| Feb 2026 | +0.3% |
| Nov 2025 | -1.8% |
| Aug 2025 | -2.9% |
| May 2025 | -3.5% |
| Feb 2025 | -7.5% |
| Nov 2024 | -9.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ANGO
| FY May 2026 | n/a |
| FY May 2025 | n/a |
| FY May 2024 | n/a |
| FY May 2023 | n/a |
| FY May 2022 | n/a |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-05 | 2025-05 | 2024-05 | 2023-05 | |
|---|---|---|---|---|
| Revenue | $320.2M | $292.5M | $303.9M | $338.8M |
| Gross profit | $174.9M | $157.7M | $154.7M | $174.2M |
| Operating income | -$39.9M | -$40.0M | -$192.4M | -$51.2M |
| Net income | -$36.7M | -$34.0M | -$184.3M | -$52.4M |
| EPS (diluted) | -0.88 | -0.83 | -4.59 | -1.33 |
| Operating cash flow | $3.1M | -$10.1M | -$28.2M | $78.0K |
| Cash | $53.9M | $55.9M | $76.1M | $44.6M |
| Long-term debt | n/a | n/a | $0 | $49.8M |
| Buybacks | $0 | $1.7M | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
ANGO Stock Sonar score 6/7 axes
Find similar shapesCompareANGO ranks highest on financial health (99th percentile) and institutional and government (59th), and lowest on insider conviction (22nd), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ANGO filings, in plain words
Are Angiodynamics insiders buying or selling ANGO?
In the 180 days to 2026-10-28, Angiodynamics insiders were net sellers, a net $344.0K across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded ANGO?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Debbie Wasserman Schultz dated 2025-07-16.
Are there planned insider sales of ANGO?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $344.0K of stock; the latest, by WARREN NIGHAN, was filed 2026-07-30.
Read the full summary
In the 180 days to 2026-10-28, Angiodynamics insiders were net sellers of ANGO, a net $344.0K across purchases and sales reported on Form 4 by 1 seller. Members of Congress have disclosed trades in ANGO, none in the last year; the latest on record is a sale by Debbie Wasserman Schultz dated 2025-07-16. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $344.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
